Jingwen Wei

Jingwen Wei

Auto-generated profile, based on publicly available information

Jingwen Wei

Department of Urology and Institute of Urology, West China Hospital Sichuan University Chengdu Sichuan People's Republic of China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2024 in Clinical and Translational Medicine
Verified
Journal Article
Open access
XDXingpeng Di
Xingpeng Di
JCJiawei Chen
Jiawei Chen
YLYa Li
Ya Li
MWMenghua Wang
Menghua Wang
JWJingwen Wei
Jingwen Wei
DLDeyi Luo
Deyi Luo
Background: The impact of fibroblasts on the immune system provides insight into the function of fibroblasts. In various tissue microenvironments, multiple fibroblast subtypes interact with immunocytes by secreting growth factors, cytokines, and chemokines, leading to wound healing, fibrosis, and escape of cancer immune surveillance. However, the specific mechanisms involved in the fibroblast‐immunocyte interaction network have not yet been fully elucidated.Main body and conclusion: Therefore, we systematically reviewed the molecular mechanisms of fibroblast‐immunocyte interactions in fibrosis, from the history of cellular evolution and cell subtype divisions to the regulatory networks between fibroblasts and immunocytes. We also discuss how these communications function in different tissue and organ statuses, as well as potential therapies targeting the reciprocal fibroblast‐immunocyte interplay in fibrosis. A comprehensive understanding of these functional cells under pathophysiological conditions and the mechanisms by which they communicate may lead to the development of effective and specific therapies targeting fibrosis.

14 December 2025 in MedComm – Oncology
Verified
Journal Article
Open access
YLYa Li
Ya Li
XDXingpeng Di
Xingpeng Di
JCJiawei Chen
Jiawei Chen
JWJingwen Wei
Jingwen Wei
TLTianyue Li
Tianyue Li
DLDeyi Luo
Deyi Luo
Cancer‐associated fibroblasts (CAFs) in the tumor microenvironment (TME) interact with multiple immune cells, such as T cells, macrophages, neutrophils, and other immune cells, to display both antitumor or protumor effects. Despite enormous progress in immunotherapy, the CAF‐associated resistance of immunotherapy is still urgent to be solved. In this review, we summarize the origins and heterogeneity of CAFs in the TME, including the subpopulations of CAFs and their biological function. Then we discuss the communications between CAFs and tumor‐associated macrophages, T lymphocytes, tumor‐associated neutrophils, and other immune cells. CAFs cannot only recruit immune cells in the TME, but also trigger polarization, proliferation, infiltration of immune cells, thereby promoting tumor progression. Inversely, some immune cells promote the recruitment, transdifferentiation, and proliferation of CAFs. We also focus on the current progress in therapeutic strategies targeting CAF‐elimination, CAF‐reprograming, downstream signaling blockade, and CAF‐induced extracellular matrix barrier elimination to enhance the efficacy of immunotherapy and related clinical trials. Overall, we aim to provide the conceptions of CAF‐immunocyte crosstalk in the TME and application of immunotherapy, paving the way for the development of precise and individualized strategies through clarifying the interaction between CAFs and immunocytes.